COMP <GO>
CYRX vs JNJ // ENTERPRISE SCALE & MARKET CAP
CryoPort Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CYRX 3
— JNJ 8
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $18.29 (-1.88%) • MKT CAP: $926.4M
market-cap
$926.4M
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 47.10% | 67.90% | -20.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.50% | 25.50% | -37.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.70% | 2.97% | -5.67 | JNJ | /fcf-yield <GO> |
| Operating Margin | -20.90% | 34.70% | -55.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 44.40% | 28.50% | +15.90 | CYRX | /net-margins <GO> |
| Revenue Growth (YoY) | 12.40% | 6.00% | +6.40 | CYRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.33 | 5.59 | -4.26 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 62.1 | -5.50 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.9x | 23.0x | -13.10 | CYRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $926.4M | $662.49B | -$661.57B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYRX REV | JNJ REV | CYRX GROSS % | JNJ GROSS % | CYRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $176.2M | $94.19B | 47.1% | 67.9% | -$25.0M | $19.70B |
| FY 2024 | $156.8M | $88.82B | 44.4% | 69.1% | -$33.6M | $19.84B |
| FY 2023 | $168.7M | $85.16B | — | — | -$757.0K | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYRX // BETA —
JNJ // BETA 1.08